Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Meyeon Park"'
Autor:
Elise Hoover, Vanessa Holliday, Nicole Merullo, Dorothee Oberdhan, Ronald D. Perrone, Chris Rusconi, Meyeon Park, Milind A. Phadnis, Nadeesha Thewarapperuma, Neera K. Dahl
Publikováno v:
Kidney Medicine, Vol 6, Iss 5, Pp 100813- (2024)
Rationale & Objective: Autosomal dominant polycystic kidney disease (ADPKD) affects health-related quality of life (HRQoL) including pain, discomfort, fatigue, emotional distress, and impaired mobility. Stakeholders prioritized kidney cyst-related pa
Externí odkaz:
https://doaj.org/article/f4ea332d6b3a4a40bb39c6bd2ec097f8
Autor:
José M. Rodriguez‐Valadez, Malak Tahsin, Umesh Masharani, Meyeon Park, M. G. Myriam Hunink, Joseph Yeboah, Lihua Li, Ellerie Weber, Asem Berkalieva, Luuk Avezaat, Wendy Max, Kirsten E. Fleischmann, Bart S. Ferket
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 4 (2024)
Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are mediated by changes in glycated hemoglobin, body weight, systolic blood
Externí odkaz:
https://doaj.org/article/78b10788b725414dbbab332b1f6a1ac1
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background Kidney transplant is the gold standard for renal replacement therapy in patients with autosomal dominant polycystic kidney disease (ADPKD), which is the fourth leading cause of kidney failure. Despite the medical and economic bene
Externí odkaz:
https://doaj.org/article/209b5e9d7a704e68bdc13011b6e37105
Autor:
Barry I. Freedman, Marva M. Moxey-Mims, Amir A. Alexander, Brad C. Astor, Kelly A. Birdwell, Donald W. Bowden, Gordon Bowen, Jonathan Bromberg, Timothy E. Craven, Darshana M. Dadhania, Jasmin Divers, Mona D. Doshi, Elling Eidbo, Alessia Fornoni, Michael D. Gautreaux, Rasheed A. Gbadegesin, Patrick O. Gee, Giselle Guerra, Chi-yuan Hsu, Ana S. Iltis, Nichole Jefferson, Bruce A. Julian, David K. Klassen, Patrick P. Koty, Carl D. Langefeld, Krista L. Lentine, Lijun Ma, Roslyn B. Mannon, Madhav C. Menon, Sumit Mohan, J. Brian Moore, Barbara Murphy, Kenneth A. Newell, Jonah Odim, Mariella Ortigosa-Goggins, Nicholette D. Palmer, Meyeon Park, Afshin Parsa, Stephen O. Pastan, Emilio D. Poggio, Nishadi Rajapakse, Amber M. Reeves-Daniel, Sylvia E. Rosas, Laurie P. Russell, Deirdre Sawinski, S. Carrie Smith, Mitzie Spainhour, Robert J. Stratta, Matthew R. Weir, David M. Reboussin, Paul L. Kimmel, Daniel C. Brennan
Publikováno v:
Kidney International Reports, Vol 5, Iss 3, Pp 278-288 (2020)
Introduction: Much of the higher risk for end-stage kidney disease (ESKD) in African American individuals relates to ancestry-specific variation in the apolipoprotein L1 gene (APOL1). Relative to kidneys from European American deceased-donors, kidney
Externí odkaz:
https://doaj.org/article/27ee292381584280a69fe14f4d3b0d74
Autor:
Mats C. H. Lassen, Atif N. Qasim, Tor Biering-Sørensen, Jacob L. T. Reeh, Terry Watnick, Stephen L. Seliger, Huanwen Chen, Mariem A. Sawan, Daniel Nguyen, Yongfang Li, Susie N. Hong, Meyeon Park
Publikováno v:
BMC Nephrology, Vol 20, Iss 1, Pp 1-11 (2019)
Abstract Background Patients with autosomal dominant polycystic kidney disease (ADPKD) have an increased risk of cardiovascular morbidity and mortality. Impaired left ventricular (LV) global longitudinal strain (GLS) can be a sign of subclinical card
Externí odkaz:
https://doaj.org/article/2ba5499ccd0c43baa351d8835f7d4633
Publikováno v:
Data in Brief, Vol 14, Iss C, Pp 366-370 (2017)
Tumor necrosis factor receptor type 1 (TNFR1) is associated with kidney disease and mortality risk in various populations [1,2]. We evaluated associations of TNFR1 with mortality and mediators of this relationship in doi: 10.1016/j.atherosclerosis.20
Externí odkaz:
https://doaj.org/article/c73b01b20b0c4dd6a6fc58c76e8373dc
Publikováno v:
BMC Nephrology, Vol 18, Iss 1, Pp 1-7 (2017)
Abstract Background Autosomal dominant polycystic kidney disease (PKD) is the most common genetic renal disease and the fourth leading cause of end-stage renal disease in the United States. Although there is no cure for PKD, several treatments are co
Externí odkaz:
https://doaj.org/article/3b30cb8ac27444e9864772be14a2b6e8
Publikováno v:
Biomarker Insights, Vol 2013, Iss 8, Pp 15-18 (2013)
Externí odkaz:
https://doaj.org/article/0af21c78cd934ab6ab0f1ea89e31ade8
Publikováno v:
Advances in Kidney Disease and Health. 30:228-235
Autor:
José M. Rodriguez-Valadez, Malak Tahsin, Kirsten E. Fleischmann, Umesh Masharani, Joseph Yeboah, Meyeon Park, Lihua Li, Ellerie Weber, Yan Li, Asem Berkalieva, Wendy Max, M.G. Myriam Hunink, Bart S. Ferket
Publikováno v:
Diabetes Care, 46(6), 1300-1310. American Diabetes Association Inc.
Diabetes Care
Diabetes Care
BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with diabetes at lower cardiovascular risk, but whether treatment benefits differ by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b39b9ead449ea030b5397d5c9d27527
https://pure.eur.nl/en/publications/d85247f5-eb59-449b-9622-17886569df44
https://pure.eur.nl/en/publications/d85247f5-eb59-449b-9622-17886569df44